Baricitinib shows promise for treating alopecia areata with mild side effects.
November 2024 in “Journal of the European Academy of Dermatology and Venereology” Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
13 citations
,
September 2018 in “Journal of the American Academy of Dermatology” The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
January 2025 in “Medical Research Archives” A new classification and scoring system is needed for alopecia areata to better assess severity.
9 citations
,
July 2010 in “Pediatric dermatology” Corticosteroids worked better than anthralin cream for hair regrowth.
March 2026 in “International Journal of Dermatology and Venereology” Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
48 citations
,
July 2023 in “Pediatric Dermatology” Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
July 2023 in “Deleted Journal” Alopecia areata is the most common type of baldness treated with corticosteroids and minoxidil.
June 1985 in “Journal of the American Academy of Dermatology” 3 citations
,
March 2024 in “Journal of Dermatological Treatment” Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.
October 2021 in “DOAJ (DOAJ: Directory of Open Access Journals)” High retinol intake may worsen hair loss in alopecia areata.
August 2025 in “Veterinary Dermatology” Canine alopecia areata is a chronic condition needing long-term management.
4 citations
,
November 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The Brigham Eyebrow Tool for Alopecia is a simple and reliable way to measure eyebrow hair loss.
October 2024 in “The Journal of Dermatology” Intravenous corticosteroid therapy is effective for long-term hair regrowth in alopecia areata, and a scoring system helps predict treatment success and relapse.
97 citations
,
January 2006 in “Dermatology” imTA and pulse therapy are effective for alopecia areata with manageable side effects, but relapse rates need improvement.
56 citations
,
June 2010 in “Clinical and experimental dermatology” Coudability hairs are useful markers for alopecia areata activity.
July 2010 in “Hair transplant forum international” The ABHRS held a test in Capri, Italy.
6 citations
,
December 2015 in “Journal of Dermatological Case Reports” Intradermal testing can better detect corticosteroid allergies than patch testing.
1 citations
,
July 2023 in “Cutis” Scalp rolling might help regrow hair in people with a hair loss condition called Alopecia Areata.
2 citations
,
September 2025 in “Frontiers in Endocrinology” SARMs show promise but need more evidence to prove they're better than traditional androgens.
August 2023 in “Journal of inflammation research” An elderly Chinese man lost all his hair after taking a new heart medication.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
2 citations
,
May 2024 in “International Journal of Medical Arts” Diphenylcyclopropenone (DPCP) is more effective than anthralin for treating resistant alopecia areata.
3 citations
,
January 2014 in “The Journal of Dermatology” Squaric acid dibutylester for alopecia areata can cause benign skin lymphoid growths.
2 citations
,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The botanical treatment for hair loss shows promise, especially for children.
March 2024 in “Dermatology and therapy” AA patients with comorbid conditions face more severe hair loss and need specific treatments.
4 citations
,
May 2025 in “Dermatology and Therapy” Baricitinib effectively improves symptoms of atopic dermatitis and alopecia areata with few side effects.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
April 2024 in “Frontiers in medicine” Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.